Matches in Nanopublications for { ?s ?p "[JAK2V617F mutation screening is indicated for the evaluation of erythrocytosis, thrombocytosis, splanchnic vein thrombosis, and otherwise unexplained BCR-ABL1-negative granulocytosis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 4 of
4
with 100 items per page.
- assertion description "[JAK2V617F mutation screening is indicated for the evaluation of erythrocytosis, thrombocytosis, splanchnic vein thrombosis, and otherwise unexplained BCR-ABL1-negative granulocytosis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP582323.RA7fS5_vl2haUpNiCCxpZ6oERjPNfo63Da1jXwd0WhnRo130_assertion description "[JAK2V617F mutation screening is indicated for the evaluation of erythrocytosis, thrombocytosis, splanchnic vein thrombosis, and otherwise unexplained BCR-ABL1-negative granulocytosis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP582323.RA7fS5_vl2haUpNiCCxpZ6oERjPNfo63Da1jXwd0WhnRo130_provenance.
- NP219550.RA86bsjE7XB6vVPzqaRHDYntd7ISFsZmbG_8hJhT7KR5k130_assertion description "[JAK2V617F mutation screening is indicated for the evaluation of erythrocytosis, thrombocytosis, splanchnic vein thrombosis, and otherwise unexplained BCR-ABL1-negative granulocytosis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP219550.RA86bsjE7XB6vVPzqaRHDYntd7ISFsZmbG_8hJhT7KR5k130_provenance.
- NP906579.RA3cbyAp1_taXIqApVxhzJQTgn1kpfbG4d74wfIvX5xwk130_assertion description "[JAK2V617F mutation screening is indicated for the evaluation of erythrocytosis, thrombocytosis, splanchnic vein thrombosis, and otherwise unexplained BCR-ABL1-negative granulocytosis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP906579.RA3cbyAp1_taXIqApVxhzJQTgn1kpfbG4d74wfIvX5xwk130_provenance.